Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration

Phase 2

Completed

• Conditions: Allergies
• Interventions: Drug: Purified allergen dose 3 integrated in a Patch system; Drug: Purified allergen integrated in a Patch system; Drug: Purified allergen dose 1 integrated in a Patch system; Drug: Purified allergen dose 2 integrated in a Patch system

• Registration Number: NCT00719511
• Lead Sponsor: University of Zurich

Brief Summary

Evaluation of patch as specific immunotherapy in allergic patients

Detailed Description

Not available

Study Timeline

• Study Start: 2008-02
• Study First Submitted: 2008-07-17
• Study First Submitted QC: 2008-07-18
• Study First Posted: 2008-07-21
• Primary Completion: 2009-11
• Study Completion: 2009-12
• Status Verified: 2011-02
• Last Update Submitted: 2011-02-16
• Last Update Posted: 2011-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
3	Purified allergen dose 3 integrated in a Patch system	Patch allergen dose 3
4	Purified allergen integrated in a Patch system	Placebo
1	Purified allergen dose 1 integrated in a Patch system	Patch allergen dose 1
2	Purified allergen dose 2 integrated in a Patch system	Patch allergen dose 2

Primary Outcome Measures

Name	Time	Method
Comparison of the efficacy of the placebo with that of three different test doses of the epicutaneous pollen allergen administration evaluated by visual analog scales after the treatment	2010